| Document |
Document Title |
|
WO/1986/005183A1 |
A compound of formula (I), wherein R1 is an amino group which may be protected R3 is a hydrogen atom or an optionally substituted hydrocarbon residue; Z is S, S$(1,3)$O, O or CH2, R4 is a hydrogen atom, methoxy group or formamido group, ...
|
|
WO/1986/003941A1 |
A method of systematically controlling endoparasites and ectoparasites of warm-blooded animals by orally or percutaneously administering to the animal a parasiticidally effective amount of an acyl urea compound.
|
|
WO/1986/002927A1 |
Compounds represented by formula (I), wherein R represents hydrogen, halogen, C1-4 alkyl, trifluoromethyl, phenyl or C1-4 alkoxy, n represents 0,1 or 2, A represents formula (II), wherein X represents halogen or optionally halogen-substi...
|
|
WO/1986/002552A1 |
A class of bicyclic benzenoid aminoalkylene ether and thioether compounds exhibiting pharmacological activity, including anti-secretory and anti-ulcerogenic activity, pharmaceutical compositions comprising these compounds, and methods fo...
|
|
WO/1986/001204A1 |
New dopamine-derivatives of general formula (I) are described, where A is a substituted phenyl group of structure (II) in which R1 and R2 at the same time or separately represent hydrogen, C1-5 alkyl and allyl, D is a compound according ...
|
|
WO/1986/000898A1 |
A dihydropyridine$(1,7)$pyridinium salt type of redox, or chemical, delivery system for the site-specific and/or site-enhanced delivery of a radionuclide to the brain. A chelating agent capable of chelating with a radionuclide and having...
|
|
WO/1986/000897A1 |
A dihydropyridine$(1,7)$pyridinium salt type of redox, or chemical, delivery system for the site-specific and/or site-enhanced delivery of a radio-nuclide to the brain. A chelating agent capable of chelating with a radionuclide and havin...
|
|
WO/1985/005105A1 |
A class of 3- and 5-amino thiatriazine compounds exhibiting pharmacological activity, including gastrointestinal anti-ulcerogenic and cytoprotective activity, pharmaceutical compositions comprising these compounds, and methods for the tr...
|
|
WO/1985/005032A1 |
A class of benzocyclobutene aminoalkylene ether and thioether compounds exhibiting pharmacological activity, including anti-secretory and anti-ulcerogenic activity, pharmaceutical compositions comprising these compounds, and methods for ...
|
|
WO/1984/004921A1 |
Substituted benzopentathiepins, their preparation from 1, 2, 3-benzothiadiazoles and elemental sulfur, selected 1, 2, 3-benzothiadiazoles; the benzopentathiepins being useful as intermediates to 1, 2-benzenedithiols or as agricultural an...
|
|
WO/1984/004247A1 |
A class of bicyclic benzenoid aminoalkylene ether and thioether compounds exhibiting pharmacological activity, including anti-secretory and anti-ulcerogenic activity, pharmaceutical compositions comprising these compounds, and methods fo...
|
|
WO/1984/004245A1 |
A class of naphthalene aminoalkylene ether and thioether compounds exhibiting pharmacological activity including anti-secretory and anti-ulcerogenic activity, pharmaceutical compositions comprising these compounds, and methods for the tr...
|
|
WO/1984/002525A1 |
Novel compounds having formula (I), wherein R is lower alkyl, lower cycloalkyl, lower haloalkyl, lower alkylcarboxymethyl, arylcarboxymethyl, lower alkenyl, lower alkynyl, aryl having from 6 to about 10 carbon atoms, or aralkyl; R1 is lo...
|
|
WO/1983/001772A1 |
Compounds of the formula$(10,)$wherein R1 is lower alkyl, lower cycloalkyl, lower alkenyl, lower alkynyl, lower alkyl carboxymethyl, aryl carboxymethyl, aryl, or aralkyl; A is a direct bond, lower alkylene, or lower alkenylene; x is 1 or...
|
|
WO/1982/001000A1 |
Intramolecular or intermolecular disulfide compounds of compounds represented by the following general formula (I): (FORMULA) wherein R1 and R2 each represent a hydrogen atom, a lower alkyl group, an aryl group, an aralkyl group, a lower...
|
|
WO1982000096A1 |
Process and composition for reducing intraocular pressure and reducing aqueous humor formation by applying topically to the cornea an effective amount of an aqueous solution of a carbonic anhydrase inhibitor comprising a sulfonamide havi...
|
|
WO/1979/000829A1 |
Thiadiazine compounds of the formula (I) (FORMULA) wherein R1 is alkyl, R2 is alkyl, cycloalkyl, alkenyl or aryl, R3 is alkyl and R4 is alkyl, are useful as insecticides. The thiadiazine compounds are prepared by the addition of a dialky...
|
|
WO/1979/000435A1 |
The production of zinc and/or cerium salts of known sulfonylurea oral hypoglycemic agents is accomplished by reaction of water soluble zinc salts with alkali metal salts of the sulfonylurea derivatives. The resulting zinc and/or cerium s...
|
|
JP2024513606A |
The present invention relates to formula (I) (wherein A, Z, L, R1,R2,R3,R4,R5and R33is defined in claim 1), or a pharmaceutically acceptable salt thereof. Compounds of formula (I) have utility as inhibitors of TEAD. The present compounds...
|
|
JP2024512428A |
The present invention relates to compounds that can be used to treat viral infections. The compound is a papain-like protease (PLpro) inhibitor.
|
|
JP2024512576A |
The disclosure features novel lipids and compositions containing them. Lipid nanoparticles (eg, hollow LNPs or loaded LNPs) contain, in addition to novel lipids, additional lipids such as phospholipids, structured lipids, and PEG lipids....
|
|
JP2024032685A |
The present invention provides a heterocyclic compound for liquid crystals. The present invention provides a compound of formula I, a liquid crystalline medium containing the compound, a device for shifting the phase of microwaves, a tun...
|
|
JP7440486B2 |
The invention relates to thiadiazine derivatives, or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof, as well as to pharmaceutical compos...
|
|
JP2024023301A |
The present invention provides novel compounds effective for controlling pests. The molecule of formula 1, as well as its N-oxides, agriculturally acceptable acid addition salts, salt derivatives, solvates, ester derivatives, crystalline...
|
|
JP2024501814A |
Crystalline and amorphous forms of lineilixibat and pharmaceutical compositions containing the same are disclosed. Methods of its preparation and methods of its use are also disclosed. Solubility and dissolution information for linerixib...
|
|
JP2024501625A |
In particular, the structure of formula (X) or a pharmaceutically acceptable salt thereof, compositions containing the same, and methods of use are provided. Ring A, L1,L2,W,R2A,R2Band R10is as described herein.
|
|
JP2024500309A |
The present invention relates to certain 1,5-benzothiazepines and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators with apical sodium-dependent bile acid transporter (ASBT) and/or hepatic b...
|
|
JP2023182866A |
To provide a cross-coupling reaction method in which various kinds of compounds can be used as starting materials, and a reaction product can be obtained in a short time and at a high yield, and a novel compound obtained by the method.A ...
|
|
JP2023552793A |
The present invention provides RXFP1 modulators for the treatment of heart failure, heart failure with preserved ejection fraction, heart failure with mildly reduced ejection fraction, heart failure with reduced ejection fraction, chroni...
|
|
JP2023179389A |
To provide a compound for treating and preventing diseases and conditions including heart failure, heart failure with a maintained ejection fraction, heart failure with a mildly reduced ejection fraction, heart failure with a reduced eje...
|
|
JP7391048B2 |
The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (...
|
|
JP7387818B2 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
JP2023547770A |
The present disclosure provides compounds, pharmaceutical compositions comprising such compounds, and methods or treatments for the treatment of inflammatory diseases and certain neurological disorders associated with inflammatory signal...
|
|
JP7369140B2 |
The present disclosure relates to thiazole- or diathiazole-substituted aryl and heteroaryl compounds (I), pharmaceutical compositions containing them, and methods of using them, including treatment of disorders or disease related to regu...
|
|
JP2023543924A |
The present invention relates to compounds of formula I, or pharmaceutically acceptable salts or solvates thereof, which are useful in the treatment of diseases or health conditions ameliorated by activation of AMPK, particularly as prod...
|
|
JP2023543498A |
A method for treating eye diseases, e.g., eye diseases associated with lipid accumulation, using a lipid-binding protein-based conjugate such as CER-001; Compositions comprising lipid-binding protein-based complexes as carriers for, and ...
|
|
JP2023145722A |
To provide molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions containing such molecules, and pr...
|
|
JP2023542503A |
Use herein for inhibiting protein tyrosine phosphatases, such as protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), as well as for the treatment of PTPN1 or PTPN2 inh...
|
|
JP7356568B2 |
The present invention provides: an actinic ray-sensitive or radiation-sensitive resin composition, represented by specific general formula (1), containing (A) a resin, and (B) a compound that produces an acid when irradiated with actinic...
|
|
JP2023541345A |
The present invention relates to compounds for use in the reactivation of butyrylcholinesterase. Such compounds are useful in the treatment or prevention of poisoning by at least one organophosphorus nerve agent. The invention also relat...
|
|
JP2023121895A |
To provide a condensed chalcogenadiazole compound that can be used in an organic transistor element producible by an application process, excels in solubility to organic solvent and heat resistance, and shows n-type semiconductor propert...
|
|
JP7310071B2 |
The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit t...
|
|
JP2023092018A |
To provide a near-infrared light-emitting composition capable of decreasing the drive voltage of an element while exhibiting high luminous efficiency.Provided is a composition which satisfies the following formulae and includes a delayed...
|
|
JP7296954B2 |
The present invention relates to compounds of formula (I). The compounds maybe used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections.
|
|
JP2023521470A |
The present invention provides compounds of formula (I): (In the formula, R1~R3(as defined in the specification and claims). The compounds of formula (I) can be used as medicaments.
|
|
JP2023072400A |
To provide a method for controlling physiological activity of a macrocycle which can use light for releasing a catenane structure.A method for controlling physiological activity of a macrocycle includes: a catenane formation step of mixi...
|
|
JP2023055771A |
To provide compounds, compositions and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for tr...
|
|
JP2023515095A |
This application describes substituted aryl compounds and pharmaceutically acceptable salts thereof that are RAD51 inhibitors. The compounds have the structure of Formula (I) and have the substituents and structural features described he...
|
|
JP2023052094A |
To provide compounds and compositions for treating cancer, type-2 diabetes, obesity, a metabolic disease, or any other disease, disorder or ailment favorably responsive to PTPN2 or PTPN1 inhibitor treatment, and methods of treating the d...
|
|
JP7254297B2 |
Provided are a donor-acceptor type compound having a novel structure and its use.An enamine compound represented by general formula (1)(in the formula:R1represents an electron-withdrawing group;A represents a divalent aromatic hydrocarbo...
|
